AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2019
Apr 9, 2019
31580_dirs_2019-04-09_65cfa6b9-88d0-40e7-98df-2e83de2c9e72.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2019-04-05
Reporting Person: Biller Scott (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-04-05 | Common stock | M | 3000 | $39.76 | Acquired | 29511 | Direct |
| 2019-04-05 | Common stock | S | 2401 | $67.61 | Disposed | 27110 | Direct |
| 2019-04-05 | Common stock | S | 599 | $68.12 | Disposed | 26511 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-04-05 | Stock option (right to buy) | $39.76 | M | 3000 | Disposed | 2026-02-15 | Common stock (3000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common stock | 53059 | Indirect |
Footnotes
F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $67.00 to $67.99. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $68.00 to $68.27. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F5: Shares held by a trust, of which the reporting person is trustee and beneficiary.
F6: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.